Navigation Links
Sonus Pharmaceuticals Receives Favorable NASDAQ Decision

BOTHELL, Wash., July 17 /PRNewswire-FirstCall/ -- Sonus Pharmaceuticals, Inc. (Nasdaq: SNUS) today announced that it received a notice from the NASDAQ Listing Qualifications Hearings Panel on July 16, 2008 indicating that the NASDAQ Panel has determined to grant Sonus' request to continue the listing of its securities on The NASDAQ Global Market. The Company's continued listing on NASDAQ is subject to its compliance with certain conditions by August 29, 2008, including the implementation of a reverse stock split, the completion of its planned merger with OncoGenex Technologies Inc., and approval from NASDAQ of the combined entity's application for initial listing on The NASDAQ Capital Market upon completion of the merger.

"This extension provides the time to implement the resolutions we have proposed to shareholders, including the issuance of shares to consummate the merger with OncoGenex and the reverse stock split, which together we believe will better position the new company to maintain listing on The NASDAQ Capital Market. All of which we believe are in the best interests of shareholders," said Michael A. Martino, President and CEO.

The NASDAQ Panel's exception is subject to certain conditions, such as requiring Sonus to inform the NASDAQ Panel of any significant events that may impact Sonus' ability to maintain compliance with the NASDAQ listing requirements or the exception deadline, and is subject to review by the NASDAQ Listing and Hearing Review Council for a period of 45 days from the date of the NASDAQ Panel's determination letter. Sonus expects to be able to comply with the NASDAQ Panel's conditions for continued listing on The NASDAQ Global Market; however, there can be no assurance that Sonus will be able to do so. Failure to comply with the conditions for listing could result in the delisting of Sonus' shares from NASDAQ.

About Sonus Pharmaceuticals, Inc.

Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of cancer drugs that are designed to provide better efficacy, safety and tolerability, and ease of use. Sonus moved an oncology product candidate, SN2310, into a Phase 1 clinical trial in September 2006. For additional information on Sonus, including past news releases, please visit

About OncoGenex Technologies Inc.

OncoGenex Technologies Inc. is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. OGX-427 has begun evaluation in Phase 1 clinical studies, while the third product candidate, OGX-225, has completed preclinical pharmacology studies. More information is available at

Definitive Agreement to Merge

On May 28, 2008, Sonus and OncoGenex jointly announced the signing of a definitive agreement to merge the two companies. The proposed transaction is expected to be completed prior to August 29, 2008, subject to the satisfaction of certain conditions, including the approval of Sonus' and OncoGenex' shareholders and, in the case of OncoGenex, court approval under the arrangement provisions of the Canada Business Corporations Act.

Forward-Looking Statements

Certain statements made in this press release are forward-looking such as those, among others, relating to the listing of the Sonus' stock on The NASDAQ Capital Market and the timing of the merger with OncoGenex. Actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the ability of Sonus to obtain shareholder approval of the issuance of shares in connection with the merger with OncoGenex or the reverse stock split, volatility in the value of Sonus' common stock, the potential inability of Sonus and OncoGenex to complete the merger, and the ability of Sonus to meet the initial listing standards of The NASDAQ Capital Market. A more complete discussion of risks and uncertainties that may affect forward-looking statements is included in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2007, its Quarterly Report on Form 10-Q for the first quarter of 2008, and its definitive proxy statement filed July 3, 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

SOURCE Sonus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
2. Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
3. Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering
4. Amylin Pharmaceuticals to Webcast Second Quarter Results
5. ViroPharma To Acquire Lev Pharmaceuticals
6. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
7. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
8. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
9. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
10. Alexion Pharmaceuticals Invites You to Participate in its Second Quarter 2008 Results Conference Call and Web Cast
11. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
Post Your Comments:
(Date:6/27/2016)... -- Alex,s Lemonade Stand Foundation (ALSF), a leading national childhood ... state-of-the-art bioinformatics lab, using ,big data, to advance the ... Liz Scott , co-executive director of ALSF and ... Washington, D.C. , hosted by Vice ... of pediatric cancer research and awareness. ...
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
Breaking Biology Technology:
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):